Literature DB >> 18354940

Pattern of eclampsia in a tertiary health facility situated in a semi-rural town in Northern Nigeria.

J Tukur1, B A Umar, A Rabi'u.   

Abstract

BACKGROUND/
OBJECTIVE: To determine the pattern of eclampsia and its contribution to maternal mortality at the Federal Medical Centre, Birnin Kudu, Jigawa State in Northern Nigeria.
METHOD: A 4-year retrospective review of the case records of all women who presented with eclampsia at the center. All the case records were retrieved from the medical record department and analyzed.
RESULTS: There were 207 cases of eclampsia out of 2197 deliveries during the period giving an incidence of 9.42%. 171 (82.6%) of the patients were unbooked. Majority (58.5%) of the patients were aged less than 20 years. The highest frequency (78.3%) was recorded in the primigravida. Delay before reaching the hospital was established in 116 (56%) of patients. The condition was antepartum in 68 (32.9%), intrapartum in 112 (54.1%) and postpartum in 27 (13%). 107 (51.7%) of the patients were delivered by cesarean section. Twenty two (10.6%) of the mothers died. Eclampsia was the commonest cause of maternal mortality and contributed 43.1% of all maternal deaths. 180 (87%) of the babies were delivered alive while 27 (13%) died.
CONCLUSION: Eclampsia is a major cause of maternal mortality. There is need for health education on the need for patients to avail themselves of antenatal care.

Entities:  

Mesh:

Year:  2007        PMID: 18354940     DOI: 10.4103/1596-3519.55703

Source DB:  PubMed          Journal:  Ann Afr Med        ISSN: 0975-5764


  9 in total

1.  Monitoring severe pre-eclampsia and eclampsia treatment in resource poor countries: skilled birth attendant perception of a new treatment and monitoring chart (LIVKAN chart).

Authors:  Charles A Ameh; Christine I Ekechi; Jamilu Tukur
Journal:  Matern Child Health J       Date:  2012-07

2.  Maternal and fetal outcomes after introduction of magnesium sulphate for treatment of preeclampsia and eclampsia in selected secondary facilities: a low-cost intervention.

Authors:  Jamilu Tukur; Babatunde Ahonsi; Salisu Mohammed Ishaku; Idowu Araoyinbo; Ekechi Okereke; Ayodeji Oginni Babatunde
Journal:  Matern Child Health J       Date:  2013-09

3.  Benefits of using magnesium sulphate (MgSO₄) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria.

Authors:  Ekechi Okereke; Babatunde Ahonsi; Jamilu Tukur; Salisu Mohammed Ishaku; Ayodeji Babatunde Oginni
Journal:  BMC Res Notes       Date:  2012-08-08

4.  Eclampsia in rural Nigeria: The unmitigating catastrophe.

Authors:  Chidi Ochu Uzoma Esike; Ukaegbe Ikechi Chukwuemeka; Okechukwu Bonaventure Anozie; Justus Ndulue Eze; Obioma Christian Aluka; Deirdre Eilleen Twomey
Journal:  Ann Afr Med       Date:  2017 Oct-Dec

5.  Prevalence of hypertensive disorders of pregnancy and pregnancy outcomes in Sub-Saharan Africa: A systematic review and meta-analysis.

Authors:  Kasiye Shiferaw Gemechu; Nega Assefa; Bizatu Mengistie
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

6.  Magnesium sulphate therapy in eclampsia: the Sokoto (ultra short) regimen.

Authors:  Bissallah A Ekele; Danjuma Muhammed; Lawal N Bello; Ibrahim M Namadina
Journal:  BMC Res Notes       Date:  2009-08-19

7.  Serum copeptin and pregnancy outcome in preeclampsia.

Authors:  Kehinde Sola Akinlade; Isaac Oluwole Adediji; Sheu Kadiri Rahamon; Adeniran Olubukola Fawole; Olukemi Oluwatoyin Tongo
Journal:  Niger Med J       Date:  2015 Sep-Oct

8.  Clinical and Biomarkers Difference in Prepartum and Postpartum Eclampsia.

Authors:  Yifru Berhan; Gezahegn Endeshaw
Journal:  Ethiop J Health Sci       Date:  2015-07

9.  Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits.

Authors:  Chimezie Anyakora; Yetunde Oni; Uchenna Ezedinachi; Adebola Adekoya; Ibrahim Ali; Charles Nwachukwu; Charles Esimone; Victor Abiola; Jude Nwokike
Journal:  BMC Pregnancy Childbirth       Date:  2018-01-30       Impact factor: 3.007

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.